Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | STP707 |
Synonyms | |
Therapy Description |
STP707 is a siRNA-based polypeptide nanoparticle consisting of siRNAs that target TGF-beta 1 and COX-2, leading to decreased TGF-beta 1 and COX-2 signaling, potentially resulting in enhanced antitumor immune response and decreased tumor growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STP707 | STP-707|STP 707 | STP707 is a siRNA-based polypeptide nanoparticle consisting of siRNAs that target TGF-beta 1 and COX-2, leading to decreased TGF-beta 1 and COX-2 signaling, potentially resulting in enhanced antitumor immune response and decreased tumor growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05037149 | Phase I | STP707 | Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |